Valneva SE income statement VALN

Annual Quarterly

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
Weighted average shares, basic
168
+15.4%
146
+5.1%
139
+20.0%
115
+18.3%
98
Weighted average shares, diluted
168
+15.4%
146
+5.1%
139
+20.0%
115
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
VALN (Nasdaq)
Fiscal year ends
December 31
Incorporated in
France
Headquarters
Saint-Herblain, France
SEC filer status
Accelerated filer
SEC CIK
1836564

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.